OverviewSuggest Edit

Rezolute is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. Rezolute's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.

TypePublic
Founded2010
HQLouisville, CO, US
Websiterezolutebio.com

Latest Updates

Employees (est.) (Jun 2019)19(-5%)
Share Price (May 2021)$6.5(-9%)
Cybersecurity ratingAMore

Key People/Management at Rezolute

Nevan Charles Elam

Nevan Charles Elam

Chief Executive Officer & Founder
Jin Kim

Jin Kim

Chairman
Keith Vendola

Keith Vendola

CFO
Gil Labrucherie

Gil Labrucherie

Director
Philippe Fauchet

Philippe Fauchet

Director
Show more

Rezolute Office Locations

Rezolute has offices in Louisville, Bend and Redwood City
Louisville, CO, US (HQ)
1450 Infinite Dr
Bend, OR, US
2783 NW Lolo Dr #150
Redwood City, CA, US
201 Redwood Shores Pkwy #315
Show all (3)

Rezolute Financials and Metrics

Rezolute Revenue

USD

Net income (Q2, 2021)

(7.1m)

EBIT (Q2, 2021)

(7.2m)

Market capitalization (7-May-2021)

54.3m

Closing stock price (7-May-2021)

6.5

Cash (31-Dec-2020)

37.6m

EV

17.3m
Rezolute's current market capitalization is $54.3 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cost of goods sold

1.4m2.4m2.6m1.2m1.2m882.0k

General and administrative expense

42.7k67.7k475.0k6.0m5.5m8.2m11.5m6.8m6.1m

R&D expense

3.5k34.3k4.7m9.4m12.1m17.3m19.1m14.5m

Operating expense total

42.7k71.2k509.4k10.7m15.0m20.3m28.7m25.9m20.5m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Cost of goods sold

462.4k296.4k620.1k755.5k461.6k511.7k567.4k994.4k426.1k227.6k219.2k72.9k472.6k8.9k187.0k254.0k284.0k134.0k

General and administrative expense

7.4k8.0k8.6k9.3k26.3k19.5k7.5k450.8k164.6k1.5m1.0m1.3m1.5m1.4m1.3m1.8m2.0m2.4m2.3m2.5m1.6m1.9m1.9m1.9m1.7m1.3m2.7m

R&D expense

3.0k2.2k112.6k1.6m1.3m2.0m2.5m2.3m2.5m3.1m3.4m4.3m3.4m2.5m929.9k1.3m15.1m3.2m5.0m3.7m4.5m

Operating expense total

7.4k8.0k8.6k9.3k29.4k19.5k7.5k453.0k277.2k3.1m2.3m3.3m4.1m3.7m3.8m4.9m5.4m6.7m5.8m5.0m2.6m3.2m17.0m5.2m6.7m5.1m7.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.1k527.05.9m5.3m4.1m4.5m1.6m11.6m10.0m

Accounts Receivable

8.8m

Prepaid Expenses

95.5k83.4k320.3k442.0k361.9k571.0k563.0k

Inventories

223.0k289.6k67.2k
USDQ1, 2012

Financial Leverage

1.3 x
Show all financial metrics

Rezolute Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Rezolute Online and Social Media Presence

Embed Graph

Rezolute News and Updates

Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Results allow the Company to advance development, including planning for its multiple-ascending dose clinical study Results allow the Company to advance development, including planning for its multiple-ascending dose clinical study

Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with serious unmet needs, today announced that it has entered i…

Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021

REDWOOD CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT) today presented positive results of a Phase 2a study of RZ358 in patients with post-gastric bypass hypoglycemia (PGBH), as well as results of a pharmacologic model of the drug candi…

Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts

Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA, to join board of directors as Rezolute advances lead candidate, RZ358, in congenital hyperinsulinism through late-stage clinical trials Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA, to join board of directors as …

Rezolute to Participate in Upcoming Investor Conferences in March

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following upcoming investor conferences:

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME
Show more

Rezolute Blogs

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020. Recent Business Highlights Phase 2b study of RZ358 continues to enroll congenital hyperinsulinism (HI) patients worldwide – The …

Rezolute Announces Uplisting to the Nasdaq Capital Market

Trading expected to begin November 9, 2020 REDWOOD CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (OCTQB:RZLTD), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that the Company’s common…

Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), announced today that the Company has appointed veteran global healthcare executive Philippe Fauchet, O.B.E. to its board of directors. Philippe has spent more than 35 years in the p…

Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism

REDWOOD CITY, California, July 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in the context of the global COVID-19 pandemic (“Pandemic”), including its Phase 2b study for RZ358 (“RIZ…

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety and pharmacology of …

Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher

REDWOOD CITY, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), today announced that the company has received rare pediatric disease designation (RPD) from the Food and Drug Administration (FDA) for RZ358, a potential treatment for congenital hype…
Show more

Rezolute Frequently Asked Questions

  • When was Rezolute founded?

    Rezolute was founded in 2010.

  • Who are Rezolute key executives?

    Rezolute's key executives are Nevan Charles Elam, Jin Kim and Keith Vendola.

  • How many employees does Rezolute have?

    Rezolute has 19 employees.

  • Who are Rezolute competitors?

    Competitors of Rezolute include Auxulin Pharmaceuticals, Zafgen and Araim Pharmaceuticals.

  • Where is Rezolute headquarters?

    Rezolute headquarters is located at 1450 Infinite Dr, Louisville.

  • Where are Rezolute offices?

    Rezolute has offices in Louisville, Bend and Redwood City.

  • How many offices does Rezolute have?

    Rezolute has 3 offices.